- Increasing small molecule complexity and accelerated regulatory filings timings are leading us to rethink our drug delivery and development strategy
- Computational and predictive sciences will transform all aspects of accelerated drug product development
- A focus on continuous manufacturing will revolutionise our approach to scale up and variable commercial batch sizes.
- Developing a talent blueprint for our workforce will be key to our exciting future in drug development
Brian Henry, Vice President Drug Product Design, Pfizer
